{"id":6779,"date":"2014-06-10T12:40:49","date_gmt":"2014-06-10T11:40:49","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=6779"},"modified":"2014-06-10T12:40:49","modified_gmt":"2014-06-10T11:40:49","slug":"els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","title":{"rendered":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-6783 alignleft\" alt=\"cofb.140603-05\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2014\/06\/cofb.140603-05.jpg\" width=\"367\" height=\"245\" \/><strong>Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya<\/strong>. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament de la leuc\u00e8mia mieloide aguda (LMA), donar a con\u00e8ixer les possibilitats de tractament en la malaltia de Castleman aprovades fa poc temps per la FDA, aconseguir una opini\u00f3 de la visi\u00f3 que la ind\u00fastria farmac\u00e8utica d\u00f3na de aquest grup de patologies i el paper d\u2019alguns tractaments en la terap\u00e8utica s\u00f3n els objectius de la sessi\u00f3 que va acollir el Col\u00b7legi \u201c<strong>Malalties minorit\u00e0ries: LMA i malaltia de Castleman, dos exemples d\u2019aven\u00e7os terap\u00e8utics<\/strong>\u201d coordinada per Tom\u00e0s Casas\u00edn, vocal d\u2019Hospitals del Col\u00b7legi, Roser Vall\u00e8s, vocal d\u2019Atenci\u00f3 Prim\u00e0ria, i Julio Mart\u00ednez, president de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC).<\/p>\n<p>El curs va tractar <b>aspectes cl\u00ednics de la leuc\u00e8mia mieloide aguda (LMA<\/b>) i va abordar la situaci\u00f3 actual del <b>tractament atesa la reclassificaci\u00f3 recent dels criteris diagn\u00f2stics<\/b>, fet que modifica les opcions terap\u00e8utiques i determina criteris terap\u00e8utics nous. Tamb\u00e9 va exposar els punts de vista de la ind\u00fastria farmac\u00e8utica amb relaci\u00f3 a aquestes malalties i, pel que fa a la <b>malaltia de Castleman<\/b>, es va presentar la <b>novetat terap\u00e8utica recentment aprovada per l\u2019FDA<\/b> per al tractament de la malaltia i que suposa un increment de la superviv\u00e8ncia global d\u2019aquests pacients.<\/p>\n\n<p>La formaci\u00f3, <strong>adre\u00e7ada a farmac\u00e8utics d\u2019hospitals i de centres d\u2019atenci\u00f3 prim\u00e0ria<\/strong>, va comptar amb el patrocini de <a href=\"http:\/\/www.janssen.es\/\">Janssen<\/a>. L\u2019equip docent d\u2019aquest curs, dirigit per M. Queralt Gorgas, farmac\u00e8utica de l\u2019Hospital Universitari Parc Tauli (Sabadell), va estar format per:<\/p>\n<ul>\n<li>Salut Brunet, hemat\u00f2loga del Servei Hematologia de l\u2019Hospital de Sant Pau i investigadora del Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (Barcelona).<\/li>\n<li>Ignacio Garcia, responsable de Market Acces de Janssen.<\/li>\n<li>Sara Vidal, farmac\u00e8utica del departament de Medical Affairs de Janssen.<\/li>\n<\/ul>\n<h5 style=\"text-align: right;\"><span style=\"color: #999999;\">Amb el patrocini de:<\/span><\/h5>\n<p align=\"right\"><a href=\"http:\/\/www.janssen.es\/\"><img decoding=\"async\" class=\"alignright size-full wp-image-6780\" alt=\"janssen_logo\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2014\/06\/janssen_logo.jpg\" width=\"100\" height=\"49\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6783,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[70],"class_list":["post-6779","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-formacio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-10T11:40:49+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman\",\"datePublished\":\"2014-06-10T11:40:49+00:00\",\"dateModified\":\"2014-06-10T11:40:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Formaci\u00f3\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\",\"name\":\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2014-06-10T11:40:49+00:00\",\"dateModified\":\"2014-06-10T11:40:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","og_locale":"ca_ES","og_type":"article","og_title":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2014-06-10T11:40:49+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman","datePublished":"2014-06-10T11:40:49+00:00","dateModified":"2014-06-10T11:40:49+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage"},"thumbnailUrl":"","keywords":["Formaci\u00f3"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","url":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","name":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage"},"thumbnailUrl":"","datePublished":"2014-06-10T11:40:49+00:00","dateModified":"2014-06-10T11:40:49+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/6779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=6779"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/6779\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=6779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=6779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=6779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}